William Senapedis

3.6k citations

79 papers · 2.1k indexed · h-index 29

Impact in

Hematology top 2%
- Multiple Myeloma Research and Treatments
- Acute Myeloid Leukemia Research
Geriatrics and Gerontology top 5%

Papers in

Oncology 31
- Cancer-related Molecular Pathways 17
- PARP inhibition in cancer therapy 5
Cancer Research 14
- Cancer, Hypoxia, and Metabolism 6
- Cancer, Lipids, and Metabolism 5

Co-authors: Erkan Baloglu Yosef Landesman Sharon Shacham Michael Kauffman Aristotelis Astrinidis Christian Argueta Elizabeth P. Henske Amro Aboukameel
Journals: Cancer Research (14 papers)Blood (11 papers)Molecular Cancer Therapeutics (6 papers)Journal of Clinical Oncology (6 papers)Oncotarget (5 papers)
Partner nations: United States Canada Italy

In The Last Decade

William Senapedis

77 papers receiving 2.1k citations

Peers

Countries citing papers authored by William Senapedis

Since Specialization

Citations

This map shows the geographic impact of William Senapedis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William Senapedis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William Senapedis more than expected).

Fields of papers citing papers by William Senapedis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William Senapedis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William Senapedis. The network helps show where William Senapedis may publish in the future.

Co-authors

The 25 scholars most cited alongside William Senapedis, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with William Senapedis Line = papers co-authored together William Senapedis links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Targeted transcriptional downregulation of MYC using epigenomic controllers demonstrates antitumor activity in hepatocellular carcinoma models Nature Communications ·William Senapedis, Rafaela De MendonÃƒÆ’Ã‚Â§a, Juan Castillo Pérez, Jeremiah D. Farelli, Robert Lyng, John Hodgson, Colm P. O’Donnell, Kateřina Mužíková Peřinová, Le Wang, Stephen K. Siecinski, Justin Chen, Thomas McCauley	2024	11
2	Anticancer Efficacy of KRASG12C Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of KRAS G12C-Mutant Pancreatic and Lung Cancers Molecular Cancer Therapeutics ·Husain Yar Khan, Misako Nagasaka, Amro Aboukameel, Dmitrii Pogrebnoi, Md. Hafiz Uddin, Guangqing Yang, Amanda Vaz Tostes Campos Miareli, Ibrahim Azar, Eliza W. Beal, Jian Jun Li, Steve Kim, 朱莉, Erkan Baloglu, William Senapedis, Bassel F. El‐Rayes, Philip A. Philip, Ramzi M. Mohammad, Anthony F. Shields, Mohammed Najeeb Al Hallak, Asfar S. Azmi	2023	5
3	PAK4-NAMPT Dual Inhibition Sensitizes Pancreatic Neuroendocrine Tumors to Everolimus Molecular Cancer Therapeutics ·Ronnie Hershman, Md. Hafiz Uddin, Mohammed Najeeb Al Hallak, Amro Aboukameel, Yiwei Li, Steve Kim, 朱莉, Gregory Dyson, Erkan Baloglu, William Senapedis, Yosef Landesman, Kay‐Uwe Wagner, Nerissa T. Viola, Bassel F. El‐Rayes, Philip A. Philip, Ramzi M. Mohammad, Asfar S. Azmi	2021	16
4	PAK4-NAMPT Dual Inhibition as a Novel Strategy for Therapy Resistant Pancreatic Neuroendocrine Tumors Cancers ·Ronnie Hershman, Amro Aboukameel, Irfana Muqbil, Steve Kim, 朱莉, Philip A. Philip, Ramzi M. Mohammad, Mandana Kamgar, Vinod B. Shidham, William Senapedis, Erkan Baloglu, Jing Li, Gregory Dyson, Yue Xue, Bassel F. El‐Rayes, Asfar S. Azmi	2019	24
5	Eltanexor (KPT-8602), a Second-Generation Selective Inhibitor of Nuclear Export (SINE) Compound, in Patients with Higher-Risk Myelodysplastic Syndrome Blood ·E.E. ZIMINA, Bhavana Bhatnagar, Sanjay Mohan, William Senapedis, Erkan Baloglu, Hongwei Wang, Jatin J. Shah, Sharon Shacham, Michael Kauffman	2019	4
6	Target identification of small molecules using large-scale CRISPR-Cas mutagenesis scanning of essential genes Nature Communications ·Jasper E. Neggers, Yoshiro Yamamoto, Tim Dierckx, Hiroki Noguchi, Arnout Voet, Anastasiya A. Butkovskaya, Dilek Kuzaliç, Кенджаев Шухрат Юсуфович, Nicolas Kint, Michel Delforge, Thomas Vercruysse, Erkan Baloglu, William Senapedis, Maarten Jacquemyn, Dirk Daelemans	2018	78
7	Targeting the vulnerability to NAD+ depletion in B-cell acute lymphoblastic leukemia Leukemia ·Sumiko Takao, Wenwen Chien, Vikas Madan, J. P. Sanchez, Ling‐Wen Ding, Qiao‐Yang Sun, Anand Mayakonda, Makoto Sudo, Liang Xu, Yirong Chen, Muldiasman Muldiasman, Sigal Gery, Michael Lill, H Kawai, William Senapedis, Erkan Baloglu, Markus Müschen, H. Phillip Koeffler	2017	30
8	Anticystogenic activity of a small molecule PAK4 inhibitor may be a novel treatment for autosomal dominant polycystic kidney disease Kidney International ·V. B. Safonov, Xia Zhou, Xiaonan Chen, Josephine F. Trott, Omran Abu Aboud, Kyu-Hwan Shim, 仁意桂, E Borchers-Kolb, William Senapedis, Erkan Baloglu, Moe R. Mahjoub, Xiaogang Li, Robert H. Weiss	2017	10
9	A first in human phase 1 study of KPT-9274, a first in class dual inhibitor of PAK4 and NAMPT, in patients with advanced solid malignancies or NHL Annals of Oncology ·Aung Naing, Stephen Leong, Michael J. Pishvaian, Albiruni Ryan Abdul Razak, Amit Mahipal, Suleiman Said Buba, Berhane N. Ghebretensae, William Senapedis, Sharon Shacham, Michael Kauffman, John Ellis, Joseph, Erkan Baloglu	2017	17
10	Dual and Specific Inhibition of NAMPT and PAK4 By KPT-9274 Decreases Kidney Cancer Growth Molecular Cancer Therapeutics ·Omran Abu Aboud, Ching‐Hsien Chen, William Senapedis, Erkan Baloglu, Christian Argueta, Robert H. Weiss	2016	115
11	The Second-Generation Exportin-1 Inhibitor KPT-8602 Demonstrates Potent Activity against Acute Lymphoblastic Leukemia Clinical Cancer Research ·Thomas Vercruysse, Jolien De Bie, Jasper E. Neggers, Maarten Jacquemyn, Els Vanstreels, Jonathan L. Schmid‐Burgk, Veit Hornung, Erkan Baloglu, Yosef Landesman, William Senapedis, Sharon Shacham, Antonis Dagklis, Jan Cools, Dirk Daelemans	2016	53
12	Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma Molecular Cancer Therapeutics ·Amro Aboukameel, Irfana Muqbil, William Senapedis, Erkan Baloglu, Yosef Landesman, Sharon Shacham, Michael Kauffman, Philip A. Philip, Ramzi M. Mohammad, Asfar S. Azmi	2016	74
13	XPO1 Inhibition Enhances Radiation Response in Preclinical Models of Rectal Cancer Clinical Cancer Research ·Jen Rose Smith, П.В. Ляпушкин, Ivana Kušenić, Carlos H.F. Chan, Tristan Penson, Yosef Landesman, William Senapedis, Sharon Shacham, Theodore S. Hong, James C. Cusack	2015	36
14	Targeting the Nuclear Export Protein XPO1/CRM1 Reverses Epithelial to Mesenchymal Transition Scientific Reports ·Asfar S. Azmi, Irfana Muqbil, Jack Wu, Amro Aboukameel, William Senapedis, Erkan Baloglu, Aliccia Bollig‐Fischer, Gregory Dyson, Michael Kauffman, Yosef Landesman, Sharon Shacham, Philip A. Philip, Ramzi M. Mohammad	2015	29
15	Therapeutic Potential of Targeting PAK Signaling Anti-Cancer Agents in Medicinal Chemistry ·William Senapedis, Marsha Crochiere, Erkan Baloglu, Yosef Landesman	2015	31
16	Deciphering mechanisms of drug sensitivity and resistance to Selective Inhibitor of Nuclear Export (SINE) compounds BMC Cancer ·Marsha Crochiere, Trinayan Kashyap, Ori Kalid, Sharon Shechter, Boris Klebanov, William Senapedis, Jean‐Richard Saint‐Martin, Yosef Landesman	2015	23
17	Clinical translation of nuclear export inhibitors in cancer Seminars in Cancer Biology ·William Senapedis, Erkan Baloglu, Yosef Landesman	2014	99
18	Novel Small Molecule XPO1/CRM1 Inhibitors Induce Nuclear Accumulation of TP53, Phosphorylated MAPK and Apoptosis in Human Melanoma Cells PLoS ONE ·Jennifer Yang, Matthew A. Bill, Gregory Young, Krista La Perle, Yosef Landesman, Sharon Shacham, Michael Kauffman, William Senapedis, Trinayan Kashyap, Jean‐Richard Saint‐Martin, Kari Kendra, Gregory B. Lesinski	2014	44
19	CRM1 and BRAF Inhibition Synergize and Induce Tumor Regression in BRAF-Mutant Melanoma Molecular Cancer Therapeutics ·Valery Grigoriev, Hye Won Chung, Yosef Landesman, William Senapedis, Jean‐Richard Saint‐Martin, Hensin Tsao, Keith T. Flaherty, Sharon Shacham, Michael Kauffman, James C. Cusack	2013	57
20	TACC3-TSC2 maintains nuclear envelope structure and controls cell division Cell Cycle ·Laia Gómez‐Baldó, Stephan Schmidt, Christopher A. Maxwell, Núria Bonifaci, Toni Gabaldón, Pierre‐Olivier Vidalain, William Senapedis, Aboh Andrew Ashieta, Lixia Zheng, Angelika Barnekow, Robert Rottapel, Gabriel Capellá, Marc Vidal, Aristotelis Astrinidis, Roland P. Piekorz, Miguel Ángel Pujana	2010	33

About William Senapedis

William Senapedis is a scholar working on Oncology, Cancer Research, Molecular Biology, Hematology and Geriatrics and Gerontology, having authored 79 papers that have together received 2.1k indexed citations. Recurring topics across this work include Nuclear Structure and Function (33 papers), Cancer-related Molecular Pathways (17 papers), RNA Research and Splicing (9 papers), RNA modifications and cancer (8 papers), Cancer, Hypoxia, and Metabolism (6 papers), PARP inhibition in cancer therapy (5 papers), Acute Myeloid Leukemia Research (5 papers) and Cancer, Lipids, and Metabolism (5 papers). The work is most often cited by research in Hematology (366 citations), Geriatrics and Gerontology (118 citations), Oncology (661 citations), Molecular Biology (1.6k citations) and Physiology (74 citations). William Senapedis has collaborated with scholars based in United States, Canada and Italy. Frequent co-authors include Erkan Baloglu, Yosef Landesman, Sharon Shacham, Michael Kauffman, Aristotelis Astrinidis, Christian Argueta, Elizabeth P. Henske, Amro Aboukameel, Asfar S. Azmi and Dilara McCauley. Their work appears in journals such as Cancer Research, Blood, Molecular Cancer Therapeutics, Journal of Clinical Oncology and Oncotarget.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact